On the stock market since 2021, it operates in the world of health and science. It has 1,679 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 36% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 40% a year on average.
The company sells $3.9B a year; the problem isn’t sales — it’s costs running above that number.
There is $577.9M in the vault; even if every debt were paid off, $239.9M would remain.
A loss of $724K against $3.9B in annual sales.
Over the last 12 months, executives reported 79 sells against just 22 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, ALHC sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ALHC has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.